RxDoctor Payments Data

William Klein, MD

Internal Medicine · Newport Beach, CANPI 1205834819

Payments from drug & device makers

$14,190in general payments, 2019–2025

Across 735 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AbbVie$1K
  • Grifols USA, LLC$1K
  • Boehringer Ingelheim$1K
  • Novartis$1K
  • Sanofi$953
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$14,10999%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK124$1,653
AbbVie(2 entities)61$1,112
Grifols USA, LLC53$1,099
Boehringer Ingelheim57$1,043
Novartis48$1,012
Sanofi35$953
Amgen38$701
AstraZeneca27$690
Regeneron Healthcare Solutions, Inc.24$675
Pfizer32$505
Insmed, Inc.30$414
Lilly USA, LLC19$398
Johnson & Johnson17$340
Takeda Pharmaceuticals U.S.A., Inc.13$313
Octapharma USA, Inc.12$294
Inari Medical, Inc.7$257
Merck14$216
Astellas Pharma US Inc9$191
Baxter Healthcare5$178
Genentech USA, Inc.7$162
Otsuka America Pharmaceutical, Inc.7$151
ANI Pharmaceuticals, Inc.6$147
Exact Sciences7$142
Novo Nordisk7$138
Amarin Pharma, Inc.8$125
Vifor Pharma, Inc.5$100
Mylan Specialty L.p.4$70
Shionogi Inc4$69
Advanced Respiratory, Inc2$68
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$67
Nabriva Therapeutics, PLC3$60
E.r. Squibb & Sons, L.L.C.3$60
Gilead2$59
Biohaven Pharmaceutical Holding Company Ltd.2$51
Optinose US, Inc.2$50
United Therapeutics Corporation2$43
Philips North America LLC3$42
Actelion Pharmaceuticals US, Inc.3$36
Esperion Therapeutics, Inc.2$34
Sumitomo Pharma America, Inc.2$34
Mallinckrodt Hospital Products Inc.1$32
Circassia Inc.2$30
Electromed, Inc.1$29
Pinnacle Biologics, Inc1$25
Teva Pharmaceuticals USA, Inc.2$24
Radius Health, Inc.1$23
Shire North American Group Inc1$23
Invivyd Inc1$22
Pulmonx Corporation1$22
Verona Pharma, Inc.1$21
Xeris Pharmaceuticals, Inc.1$20
Sanofi-aventis U.S. LLC1$20
Tactile Systems Technology Inc1$17
Lundbeck LLC1$17
Vyera Pharmaceuticals, LLC1$16
Stryker1$15
Vertiflex, Inc.1$15
Medtronic1$15
Aytu Biopharma, Inc.1$13
Melinta Therapeutics, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,190 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$205,683
Medicare patients
350
Services billed
1,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter250$256,094
EliquisApixaban90$95,870
JanuviaSitagliptin Phosphate41$47,621
MounjaroTirzepatide24$24,964
Breo ElliptaFluticasone/Vilanterol39$22,875
MyrbetriqMirabegron20$21,783
XareltoRivaroxaban15$18,924
OzempicSemaglutide19$17,480
FarxigaDapagliflozin Propanediol16$15,923
XanaxAlprazolam11$14,931
Rosuvastatin Calcium194$4,134
Levothyroxine Sodium278$3,870
SynthroidLevothyroxine Sodium40$3,816
Atorvastatin Calcium283$2,953
PremproEstrogen,con/M-Progest Acet12$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,653$278,969289 claims
PfizerEliquis, Prempro$505$98,730102 claims
MerckJanuvia$216$47,62141 claims
Lilly USA, LLCMounjaro$398$24,96424 claims
Astellas Pharma US IncMyrbetriq$191$21,78320 claims
Johnson & JohnsonXarelto$340$18,92415 claims
Novo NordiskOzempic$138$17,48019 claims
AstraZenecaFarxiga$690$15,92316 claims
AbbVieSynthroid$1,112$3,81640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →